Connect your AI

Allogene Therapeutics ALLO Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

Gilead SciencesGILD

7.4×+0.1×

PrecigenPGEN

67.7×—

CRISPR TherapeuticsCRSP

2.5×+0.9×

Sana BiotechnologySANA

6.4×+4.6×

CytomX TherapeuticsCTMX

3.2×+1.1×

Other financials

Income statement

Revenue-—

Operating income-$46.1M+29.3%

Net income-$42.6M+28.7%

EPS (diluted)-$0.18+35.7%

Balance sheet

Cash & equivalents$40.6M-23.0%

Total debt$81.1M-8.9%

Total equity$278.9M-27.6%

Total assets$396.0M-22.1%

Cash flow

Operating cash flow-$12.9M+75.6%

CapEx$9.0K-90.9%

Free cash flow-$12.9M+75.6%

Valuation

Market cap$711.02M+164%

Enterprise value$751.47M+146%

Profitability

Operating margin-1,241,813.6%-2,018,140pp

Net margin-1,170,863.6%-2,007,890pp

FCF margin-913,609.1%-1,474,890pp

Returns & leverage

Return on equity-52.3%-5.7pp

Debt / equity0.3×+0.1×

Current ratio9.6×-0.1×

Where this comes from

Calculated from Allogene Therapeutics’s reported figures.

market cap/total stockholders equity=2.1×

Based on the most recent quarter.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Allogene Therapeutics's price / book?: Allogene Therapeutics (ALLO) reported price / book of 2.1× in Q1 2026.
How has Allogene Therapeutics's price / book changed year-over-year?: Allogene Therapeutics's price / book increased by 159.1% year-over-year, from 0.8× to 2.1×.
What is the long-term trend for Allogene Therapeutics's price / book?: Over 5 years (2020 to 2025), Allogene Therapeutics's price / book has grown at a -21.6% compound annual growth rate (CAGR), from 3.5× to 1.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.